SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading
A former pharmaceutical executive traded on nonpublic information about an antipsychotic drug’s development, avoiding $1.3 ...
12 Best Nasdaq Stocks Under $20 to Buy Now
The Nasdaq has had a challenging start to 2025, with the index dropping nearly 12% YTD, as of March 13. March 10 marked its worst single-day decline in almost two years, plunging 4% as investor ...
Investing3d
Acadia Pharmaceuticals issues new employee stock awards
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a $2.9 billion market cap neuroscience company with strong financial health according to InvestingPro data, has granted inducement awards to ...
Investing5d
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress
ACADIA Pharmaceuticals Inc. continues to navigate a complex market environment, balancing the growth of its established products with the development of its pipeline. Trading at an EV/EBITDA ...
Investing4d
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company focused on central nervous system disorders, has been navigating a complex market landscape with its key products NUPLAZID and ...
Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals today
EDT Cathie Wood’s ARK Investment buys 35K shares of Recursion Pharmaceuticals (RXRX) todayOptimize Your Investment Research with ...
Did Supernus Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SUPN
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...
Investing2d
Acadia Pharmaceuticals issues new employee stock awards
SAN DIEGO - Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a $2.9 billion market cap neuroscience company with strong financial health according to InvestingPro data, has granted inducement awards to ...